Total Payments
$452,294
2021 Payments
$6,176
Companies
6
Transactions
32
Medicare Patients
182
Medicare Billing
$46,826
Payment Breakdown by Category
Research$439,157 (97.1%)
Consulting$12,572 (2.8%)
Food & Beverage$416.82 (0.1%)
Travel$106.22 (0.0%)
Education$42.00 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $439,157 | 14 | 97.1% |
| Consulting Fee | $12,572 | 8 | 2.8% |
| Food and Beverage | $416.82 | 7 | 0.1% |
| Travel and Lodging | $106.22 | 2 | 0.0% |
| Education | $42.00 | 1 | 0.0% |
Payments by Type
Research
$439,157
14 transactions
General
$13,137
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $416,747 | 13 | $0 (2021) |
| BIOVERATIV THERAPEUTICS INC. | $26,112 | 5 | $0 (2018) |
| Celgene Corporation | $6,907 | 6 | $0 (2020) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,400 | 2 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $85.59 | 5 | $0 (2021) |
| Genentech USA, Inc. | $42.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $6,176 | 10 | Bausch Health US, LLC ($3,702) |
| 2020 | $3,782 | 4 | Celgene Corporation ($3,770) |
| 2019 | $344,832 | 10 | Bausch Health US, LLC ($341,695) |
| 2018 | $97,463 | 7 | Bausch Health US, LLC ($71,351) |
| 2017 | $42.00 | 1 | Genentech USA, Inc. ($42.00) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/29/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 11/02/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 07/27/2021 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 07/01/2021 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $402.00 | General |
| 06/11/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.18 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 05/11/2021 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 04/21/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.37 | General |
| Category: Oncology | ||||||
| 03/18/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.56 | General |
| Category: Oncology | ||||||
| 03/12/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.46 | General |
| Category: Oncology | ||||||
| 08/11/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.02 | General |
| Category: Oncology | ||||||
| 01/30/2020 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $40.70 | General |
| 01/15/2020 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $3,562.50 | General |
| 01/11/2020 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $166.38 | General |
| 08/13/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $49,400.00 | Research |
| Study: 2018-3552 Lim • Category: GASTROENTEROLOGY | ||||||
| 06/24/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $51,111.80 | Research |
| Study: 2018-3552-Lim • Category: GASTROENTEROLOGY | ||||||
| 04/19/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $51,111.80 | Research |
| Study: 2018-3552 Lim • Category: GASTROENTEROLOGY | ||||||
| 02/28/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $49,400.00 | Research |
| Study: 2018-3552-Lim • Category: GASTROENTEROLOGY | ||||||
| 02/20/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $47,369.60 | Research |
| Study: 2018-3552 Lim • Category: GASTROENTEROLOGY | ||||||
| 02/07/2019 | Celgene Corporation | Luspatercept (Drug) | Consulting Fee | Cash or cash equivalent | $2,907.50 | General |
| 02/07/2019 | Celgene Corporation | Luspatercept (Drug) | Travel and Lodging | Cash or cash equivalent | $65.52 | General |
| 01/26/2019 | Celgene Corporation | Luspatercept (Drug) | Food and Beverage | In-kind items and services | $164.85 | General |
| 01/24/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $49,400.00 | Research |
| Study: 2018-3552-Lim • Category: GASTROENTEROLOGY | ||||||
| 01/07/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $43,901.40 | Research |
| Study: 2018-3552 Lim • Category: GASTROENTEROLOGY | ||||||
| 09/25/2018 | Bausch Health US, LLC | XIFIXAN (Drug) | — | Cash or cash equivalent | $49,400.00 | Research |
| Study: 2018-3552 Lim • Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 2018-3552 Lim | Bausch Health US, LLC | $241,183 | 5 |
| 2018-3552-Lim | Bausch Health US, LLC | $149,912 | 3 |
| 2018-3552- Lim | Bausch Health US, LLC | $21,951 | 1 |
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion | BIOVERATIV THERAPEUTICS INC. | $14,404 | 4 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfu | BIOVERATIV THERAPEUTICS INC. | $11,708 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 18 | 27 | $5,095 | $1,281 |
| 2021 | 2 | 50 | 82 | $27,844 | $8,203 |
| 2020 | 5 | 114 | 443 | $147,662 | $37,341 |
Total Patients
182
Total Services
552
Medicare Billing
$46,826
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 18 | 27 | $5,095 | $1,281 | 25.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 53 | $20,246 | $6,272 | 31.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 29 | $7,598 | $1,931 | 25.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 28 | 207 | $78,231 | $19,917 | 25.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 70 | $27,517 | $7,182 | 26.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 23 | 92 | $23,452 | $5,771 | 24.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 34 | 55 | $13,750 | $3,597 | 26.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 14 | 19 | $4,712 | $873.99 | 18.5% |
About Dr. Seah Lim, MD
Dr. Seah Lim, MD is a Hematology & Oncology healthcare provider based in Syracuse, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508890641.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Seah Lim, MD has received a total of $452,294 in payments from pharmaceutical and medical device companies, with $6,176 received in 2021. These payments were reported across 32 transactions from 6 companies. The most common payment nature is "" ($439,157).
As a Medicare-enrolled provider, Lim has provided services to 182 Medicare beneficiaries, totaling 552 services with total Medicare billing of $46,826. Data is available for 3 years (2020–2022), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Syracuse, NY
- Active Since 07/11/2006
- Last Updated 11/03/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1508890641
Products in Payments
- XIFAXAN (Drug) $341,695
- XIFIXAN (Drug) $71,351
- NO PRODUCT DISCUSSED (Drug) $26,112
- Luspatercept (Drug) $3,138
- OPDIVO (Biological) $85.59
- GAZYVA (Biological) $42.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Syracuse
Stephen Graziano, Md, MD
Hematology & Oncology — Payments: $289,362
Hematology & Oncology $289,362
Jade Homsi, Md, MD
Hematology & Oncology — Payments: $88,713
Hematology & Oncology $88,713
Zheng Zhou, Md, Ph.d, MD, PH.D
Hematology & Oncology — Payments: $28,263
Hematology & Oncology $28,263
Bernard Poiesz, Md, MD
Hematology & Oncology — Payments: $28,107
Hematology & Oncology $28,107
Dr. Abirami Sivapiragasam, Md, MD
Hematology & Oncology — Payments: $9,304
Hematology & Oncology $9,304
Rahul Seth, Do, DO
Hematology & Oncology — Payments: $7,132
Hematology & Oncology $7,132